325 related articles for article (PubMed ID: 37950749)
1. Chimeric antigen receptor-based immunotherapy in breast cancer: Recent progress in China.
Yu T; Lu Y; Fang J; Jiang X; Lu Y; Zheng J; Shang X; Shen H; Fu P
Cancer; 2024 Apr; 130(S8):1378-1391. PubMed ID: 37950749
[TBL] [Abstract][Full Text] [Related]
2. CAR-based immunotherapy for breast cancer: peculiarities, ongoing investigations, and future strategies.
Niu Z; Wu J; Zhao Q; Zhang J; Zhang P; Yang Y
Front Immunol; 2024; 15():1385571. PubMed ID: 38680498
[TBL] [Abstract][Full Text] [Related]
3. Current progress of chimeric antigen receptor (CAR) T versus CAR NK cell for immunotherapy of solid tumors.
Esmaeilzadeh A; Hadiloo K; Jabbari M; Elahi R
Life Sci; 2024 Jan; 337():122381. PubMed ID: 38145710
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic viruses improve cancer immunotherapy by reprogramming solid tumor microenvironment.
Zhang L; Pakmehr SA; Shahhosseini R; Hariri M; Fakhrioliaei A; Karkon Shayan F; Xiang W; Karkon Shayan S
Med Oncol; 2023 Dec; 41(1):8. PubMed ID: 38062315
[TBL] [Abstract][Full Text] [Related]
5. Chimeric antigen receptor-natural killer cell therapy: current advancements and strategies to overcome challenges.
Kong JC; Sa'ad MA; Vijayan HM; Ravichandran M; Balakrishnan V; Tham SK; Tye GJ
Front Immunol; 2024; 15():1384039. PubMed ID: 38726000
[TBL] [Abstract][Full Text] [Related]
6. Charting a killer course to the solid tumor: strategies to recruit and activate NK cells in the tumor microenvironment.
Portillo AL; Monteiro JK; Rojas EA; Ritchie TM; Gillgrass A; Ashkar AA
Front Immunol; 2023; 14():1286750. PubMed ID: 38022679
[TBL] [Abstract][Full Text] [Related]
7. Potential of chimeric antigen receptor (CAR)-redirected immune cells in breast cancer therapies: Recent advances.
Nikoo M; Rudiansyah M; Bokov DO; Jainakbaev NT; Suksatan W; Ansari MJ; Thangavelu L; Chupradit S; Zamani A; Adili A; Shomali N; Akbari M
J Cell Mol Med; 2022 Aug; 26(15):4137-4156. PubMed ID: 35762299
[TBL] [Abstract][Full Text] [Related]
8. Revolutionizing cancer immunotherapy in solid tumor: CAR engineering and single-cell sequencing insights.
Pu Z; Wang TB; Mou L
Front Immunol; 2023; 14():1310285. PubMed ID: 38090577
[TBL] [Abstract][Full Text] [Related]
9. Chimeric antigen receptor natural killer cells: a promising antitumor immunotherapy.
Wang Y; Jin S; Zhuang Q; Liu N; Chen R; Adam SA; Jin J; Sun J
MedComm (2020); 2023 Dec; 4(6):e422. PubMed ID: 38045827
[TBL] [Abstract][Full Text] [Related]
10. Immune evasion in cell-based immunotherapy: unraveling challenges and novel strategies.
Li YR; Halladay T; Yang L
J Biomed Sci; 2024 Jan; 31(1):5. PubMed ID: 38217016
[TBL] [Abstract][Full Text] [Related]
11. Involving stemness factors to improve CAR T-cell-based cancer immunotherapy.
Noraldeen SAM; Rasulova I; Lalitha R; Hussin F; Alsaab HO; Alawadi AH; Alsaalamy A; Sayyid NH; Alkhafaji AT; Mustafa YF; Shayan SK
Med Oncol; 2023 Oct; 40(11):313. PubMed ID: 37779152
[TBL] [Abstract][Full Text] [Related]
12. Advancing CAR-based immunotherapies in solid tumors: CAR- macrophages and neutrophils.
Liang Y; Xu Q; Gao Q
Front Immunol; 2023; 14():1291619. PubMed ID: 38090576
[TBL] [Abstract][Full Text] [Related]
13. The Progress and Prospects of Immune Cell Therapy for the Treatment of Cancer.
Han J; Zhang B; Zheng S; Jiang Y; Zhang X; Mao K
Cell Transplant; 2024; 33():9636897241231892. PubMed ID: 38433349
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy: a promising approach for glioma treatment.
Yasinjan F; Xing Y; Geng H; Guo R; Yang L; Liu Z; Wang H
Front Immunol; 2023; 14():1255611. PubMed ID: 37744349
[TBL] [Abstract][Full Text] [Related]
15. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy.
Pan K; Farrukh H; Chittepu VCSR; Xu H; Pan CX; Zhu Z
J Exp Clin Cancer Res; 2022 Mar; 41(1):119. PubMed ID: 35361234
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer immunotherapy: a comprehensive review.
Keshavarz S; Wall JR; Keshavarz S; Vojoudi E; Jafari-Shakib R
Clin Exp Med; 2023 Dec; 23(8):4431-4447. PubMed ID: 37658246
[TBL] [Abstract][Full Text] [Related]
17. Glioblastoma Immunotherapy: A Systematic Review of the Present Strategies and Prospects for Advancements.
Agosti E; Zeppieri M; De Maria L; Tedeschi C; Fontanella MM; Panciani PP; Ius T
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894718
[TBL] [Abstract][Full Text] [Related]
18. [Advances of CAR-T cell therapy in treating colorectal cancer].
Chao Z; Liu W; Liu Y
Sheng Wu Gong Cheng Xue Bao; 2024 May; 40(5):1365-1379. PubMed ID: 38783803
[TBL] [Abstract][Full Text] [Related]
19. Recent Advances in CAR-Based Solid Tumor Immunotherapy.
Shin MH; Oh E; Kim Y; Nam DH; Jeon SY; Yu JH; Minn D
Cells; 2023 Jun; 12(12):. PubMed ID: 37371075
[TBL] [Abstract][Full Text] [Related]
20. CAR-NK cells for cancer immunotherapy: recent advances and future directions.
Li T; Niu M; Zhang W; Qin S; Zhou J; Yi M
Front Immunol; 2024; 15():1361194. PubMed ID: 38404574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
